Eptinezumab Anti-CGRP monoclonal antibody Treatment of migraine

被引：0

作者：

Lu, Lingyun ^{[1
]}

Liu, Meijun ^{[2
]}

Hu, Songshan ^{[1
]}

Liu, Yao ^{[3
]}

Yang, Dongdong ^{[2
]}

Hong, Peiwei ^{[4
]}

机构：

[1] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China

[2] Chengdu Univ Tradit Chinese Med, Affiliated Hosp 1, Chengdu, Sichuan, Peoples R China

[3] Xindu Hosp Tradit Chinese Med, Chengdu, Sichuan, Peoples R China

[4] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China

来源：

DRUGS OF THE FUTURE | 2017年 / 42卷 / 10期

关键词：

Eptinezumab; ALD-403; Anti-CGRP; Antimigraine drugs; GENE-RELATED PEPTIDE; RANDOMIZED CONTROLLED-TRIAL; RECEPTOR ANTAGONIST; DOUBLE-BLIND; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; TELCAGEPANT; EFFICACY; SAFETY; TOLERABILITY;

D O I：

10.1358/dof.2017.042.10.2701433

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Eptinezumab (ALD-403) is a genetically engineered, humanized, desialylated anti-calcitonin gene-related peptide (CGRP) IgG1 monoclonal antibody that selectively binds to both a and beta forms of human CGRP, which is a promising therapeutic target for migraine. Pharmacokinetic data indicated that monthly dosing of an intravenous eptinezumab infusion could maintain bioactive levels and blood concentration for a long time. Phase I and II studies evaluating the safety and efficacy of eptinezumab in episodic and chronic migraine were completed with encouraging results, and there are currently three large phase III studies ongoing. This review summarizes the clinical trials already conducted or ongoing and the initial findings regarding the safety and efficacy of eptinezumab for the treatment of migraine.

引用

页码：609 / 615

页数：7

共 50 条

[1] Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Migraine
Hennessy, Elise
Salim, Amira
Biswas, Sudipa
Suneja, Aarushi
Mays, Maryann
Ahmed, Zubair
Mata, Ignacio
[J]. NEUROLOGY, 2023, 100 (17)
[2] Synergism of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in the treatment of migraine
Hennessy, E.
Salim, A.
Biswas, S.
Sonneborn, C.
Hogue, O.
Suneja, A.
Mays, M.
Ahmed, Z.
Mata, I
[J]. HEADACHE, 2023, 63 : 170 - 171
[3] The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
Fred Cohen
Hsiangkuo Yuan
E. M. G. DePoy
Stephen D. Silberstein
[J]. Neurotherapeutics, 2022, 19 : 922 - 930
[4] The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
Cohen, Fred
Yuan, Hsiangkuo
DePoy, E. M. G.
Silberstein, Stephen D.
[J]. NEUROTHERAPEUTICS, 2022, 19 (03) : 922 - 930
[5] Failure of an anti-CGRP monoclonal antibody in the treatment of migraine. Is it worthwhile trying another one?
Lopez-Moreno, Yolanda
Castro-Sanchez, M., V
Garcia-Trujillo, Lucia
Serrano-Castro, Pedro
[J]. REVISTA DE NEUROLOGIA, 2022, 75 (04) : 87 - 91
[6] Safety concerns of treatment with anti-CGRP monoclonal antibodies in patients with migraine
van der Arend, Britt W. H.
van Veelen, Nancy
de Ruijter, Joelle E. T.
Olsen, Michael H.
van den Brink, Antoinette Maassen
Terwindt, Gisela M.
[J]. CEPHALALGIA, 2023, 43 (1supp) : 233 - 233
[7] Efficacy and Safety of Anti-CGRP Monoclonal Antibodies for Migraine Preventative Treatment
Salim, Amira
Najjar, Atia
Ahmed, Zubair
Mata, Ignacio
[J]. NEUROLOGY, 2023, 100 (17)
[8] Anti-CGRP monoclonal antibodies in migraine: current perspectives
Giamberardino, Maria Adele
Affaitati, Giannapia
Curto, Martina
Negro, Andrea
Costantini, Raffaele
Martelletti, Paolo
[J]. INTERNAL AND EMERGENCY MEDICINE, 2016, 11 (08) : 1045 - 1057
[9] Anti-CGRP monoclonal antibodies: breakthrough in migraine therapeutics
Krishnaswamy, Ratna
Malik, Bilal Haider
Khan, Safeera
Gupta, Deepti
Islam, Muhammad
Mandel, Shrawan Kumar
Rutkofsky, Ian H.
[J]. PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2019, 23 (03) : 26 - 33
[10] Anti-CGRP monoclonal antibodies in migraine: current perspectives
Maria Adele Giamberardino
Giannapia Affaitati
Martina Curto
Andrea Negro
Raffaele Costantini
Paolo Martelletti
[J]. Internal and Emergency Medicine, 2016, 11 : 1045 - 1057

← 1 2 3 4 5 →